These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 15759045

  • 1. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.
    Sin DD, Man SF.
    Can J Physiol Pharmacol; 2005 Jan; 83(1):8-13. PubMed ID: 15759045
    [Abstract] [Full Text] [Related]

  • 2. [Chronic obstructive pulmonary disease and cardiovascular system].
    Gürgün A, Gürgün C.
    Tuberk Toraks; 2008 Jan; 56(4):464-71. PubMed ID: 19123087
    [Abstract] [Full Text] [Related]

  • 3. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease.
    Sin DD, Man SF.
    Curr Opin Pulm Med; 2008 Mar; 14(2):115-21. PubMed ID: 18303420
    [Abstract] [Full Text] [Related]

  • 4. Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease.
    van Dijk WD, Heijdra Y, Scheepers PT, Lenders JW, van Weel C, Schermer TR.
    Med Hypotheses; 2010 Feb; 74(2):277-80. PubMed ID: 19800175
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment.
    Wood-Baker R, Cochrane B, Naughton MT.
    Intern Med J; 2010 Feb; 40(2):94-101. PubMed ID: 19849745
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients.
    Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, She D.
    Ann Epidemiol; 2006 Jan; 16(1):63-70. PubMed ID: 16039877
    [Abstract] [Full Text] [Related]

  • 7. Systemic consequences of COPD.
    Tkác J, Man SF, Sin DD.
    Ther Adv Respir Dis; 2007 Oct; 1(1):47-59. PubMed ID: 19124347
    [Abstract] [Full Text] [Related]

  • 8. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease.
    Gershon AS, Wang L, To T, Luo J, Upshur RE.
    COPD; 2008 Aug; 5(4):229-34. PubMed ID: 18671148
    [Abstract] [Full Text] [Related]

  • 9. Systemic inflammation and mortality in chronic obstructive pulmonary disease.
    Sin DD, Man SF.
    Can J Physiol Pharmacol; 2007 Jan; 85(1):141-7. PubMed ID: 17487253
    [Abstract] [Full Text] [Related]

  • 10. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
    Lee TA, Schumock GT, Bartle B, Pickard AS.
    Pharmacotherapy; 2009 Sep; 29(9):1039-53. PubMed ID: 19698009
    [Abstract] [Full Text] [Related]

  • 11. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
    Akazawa M, Biddle AK, Stearns SC.
    Clin Ther; 2008 Sep; 30 Spec No():1003-16. PubMed ID: 18640475
    [Abstract] [Full Text] [Related]

  • 12. [Cardiovascular comorbidity in COPD].
    Cataluña JJ, García MA.
    Arch Bronconeumol; 2009 Sep; 45 Suppl 4():18-23. PubMed ID: 20116745
    [Abstract] [Full Text] [Related]

  • 13. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 14. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease?
    Stone IS, Barnes NC, Petersen SE.
    Heart; 2012 Jul; 98(14):1055-62. PubMed ID: 22739636
    [Abstract] [Full Text] [Related]

  • 15. [Chronic obstructive pulmonary disease and cardiovascular diseases].
    Passowicz-Muszyńska E, Gostkowska-Malec A, Jankowska R, Piesiak P.
    Pneumonol Alergol Pol; 2010 Jul; 78(1):28-32. PubMed ID: 20162516
    [Abstract] [Full Text] [Related]

  • 16. [Pneumology. Should we fear inhaled anticholinergic bronchodilators?].
    Rochat T, Janssens JP.
    Rev Med Suisse; 2009 Jan 14; 5(186):135-7. PubMed ID: 19238933
    [Abstract] [Full Text] [Related]

  • 17. [Pulmonary hypertension and pulmonary embolism in chronic obstructive pulmonary disease].
    Passowicz-Muszyńska E, Gostkowska-Malec A, Jankowska R.
    Pol Merkur Lekarski; 2009 Aug 14; 27(158):136-9. PubMed ID: 19856881
    [Abstract] [Full Text] [Related]

  • 18. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality.
    Sin DD, Man SF.
    Proc Am Thorac Soc; 2005 Aug 14; 2(1):8-11. PubMed ID: 16113462
    [Abstract] [Full Text] [Related]

  • 19. [Chronic obstructive pulmonary disease and cardiovascular disease: role of the systemic inflammation].
    Rossi FF, Pedone C, Antonelli Incalzi R.
    Recenti Prog Med; 2011 Mar 14; 102(3):109-13. PubMed ID: 21572482
    [Abstract] [Full Text] [Related]

  • 20. The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers.
    Mancini GB.
    Can J Cardiol; 2005 May 01; 21(6):519-23. PubMed ID: 15917881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.